Johnson & Johnson (JNJ)vsVSee Health, Inc. (VSEE)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
VSEE
VSee Health, Inc.
$0.19
+2.22%
HEALTHCARE · Cap: $9.01M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 659092% more annual revenue ($96.36B vs $14.62M). JNJ leads profitability with a 21.8% profit margin vs -100.6%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
VSEE
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Intrinsic value data unavailable for VSEE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -542.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : VSEE
The strongest argument for VSEE centers on Debt/Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : VSEE
The primary concerns for VSEE are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while VSEE is a turnaround play — different risk/reward profiles.
VSEE carries more volatility with a beta of 0.65 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 32/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →VSee Health, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
VSee Health, Inc. is a leading innovator in the telehealth sector, offering secure, user-friendly video communication solutions tailored for healthcare providers and patients. Its comprehensive platform encompasses a range of functionalities such as remote patient monitoring, asynchronous messaging, and seamless electronic medical record (EMR) interoperability, all designed to enhance the efficiency and quality of healthcare delivery across various specialties. With a strong commitment to improving patient engagement and accessibility, VSee caters to a diverse global clientele, positioning itself to capitalize on the growing demand for virtual care in the evolving healthcare landscape. As the industry shifts towards digital solutions, VSee Health is poised for significant growth through its cutting-edge technology and strategic initiatives.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?